Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (8): 98-102.doi: 10.6040/j.issn.1671-7554.0.2022.0699
Previous Articles Next Articles
CHEN Shihong, JIANG Dongqing, ZHUANG Xianghua, LI Xiaobo, PAN Zhe, SUN Aili, LOU Nengjun, WANG Dianhui, DU Jiaojiao, SONG Yuwen
CLC Number:
| [1] Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis [J]. Lancet, 2015, 386(10003): 1565-1575. [2] Lleo A, Leung PSC, Hirschfield GM, et al. The pathogenesis of primary biliary cholangitis: a comprehensive review [J]. Semin Liver Dis, 2020, 40(1): 34-48. [3] 陈成伟, 成军, 窦晓光, 等. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12):1980-1988. [4] Angulo P. Strengthening the bones in primary biliary cirrhosis [J]. Hepatology, 2013, 58(6): 1871-1873. [5] 夏维波, 章振林, 林华, 等. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5): 413-444. [6] Liu H, Liu Y, Wang L, et al. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China [J]. BMC Gastroenterol, 2010, 10: 100. doi: 10.1186/1471-230X-10-100. [7] 张奉春, 王立, 帅宗文, 等. 原发性胆汁性胆管炎诊疗规范(2021)[J]. 中华内科杂志, 2021 60(8): 709-715. [8] Glass LM, Su GL. Metabolic bone disease in primary biliary cirrhosis [J]. Gastroenterol Clin North Am, 2016, 45(2): 333-343. [9] Raszeja-Wyszomirska J, Miazgowski T. Osteoporosis in primary biliary cirrhosis of the liver [J]. Prz Gastroenterol, 2014, 9(2): 82-87. [10] Chalifoux SL, Konyn PG, Choi G, et al. Extrahepatic manifestations of primary biliary cholangitis [J]. Gut Liver, 2017, 11(6): 771-780. [11] Liao CY, Chung CH, Chu P, et al. Increased risk of osteoporosis in patients with primary biliary cirrhosis [J]. PLoS One, 2018, 13(3): e0194418. doi: 10.1371/journal.pone.0194418. [12] Guañabens N, Cerdá D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis [J]. Gastroenterology, 2010, 138(7): 2348-2356. [13] Lin CY, Cheng YT, Chang ML, et al. The extrahepatic events of Asian patients with primary biliary cholangitis: a 30-year cohort study [J]. Sci Rep, 2019, 9(1): 7577. doi: 10.1038/s41598-019-44081-x. [14] Schmidt T, Schmidt C, Schmidt FN, et al. Disease duration and stage influence bone microstructure in patients with primary biliary cholangitis [J]. J Bone Miner Res, 2018, 33(6): 1011-1019. [15] Tang R, Wei Y, Li Z, et al. A common variant in CLDN14 is associated with primary biliary cirrhosis and bone mineral density [J]. Sci Rep, 2016, 6:19877. doi: 10.1038/srep19877. [16] Seki A, Ikeda F, Miyatake H, et al. Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis [J]. J Gastroenterol Hepatol, 2017, 32(9): 1611-1616. [17] Saeki C, Oikawa T, Kanai T, et al. Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis [J]. Eur J Gastroenterol Hepatol, 2021, 33(5): 731-737. [18] Jeong HM, Kim DJ. Bone diseases in patients with chronic liver disease [J]. Int J Mol Sci, 2019, 20(17): 4270. doi: 10.3390/ijms20174270. [19] Ruiz-Gaspà S, Guañabens N, Jurado S, et al. Bilirubin and bile acids in osteocytes and bone tissue. potential role in the cholestatic-induced osteoporosis [J]. Liver Int, 2020, 40(11): 2767-2775. [20] Silvia RG, Nuria G, Susana J, et al. Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases [J]. Gene, 2020, 725: 144167. doi: 10.1016/j.gene.2019.144167. [21] Schmidt T, Schwinge D, Rolvien T, et al. Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis [J]. J Hepatol, 2019, 70(5): 941-953. [22] Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities [J]. Nat Rev Gastroenterol Hepatol. 2020, 17(2): 93-110. [23] Danford CJ, Trivedi HD, Papamichael K, et al. Osteoporosis in primary biliary cholangitis [J]. World J Gastroenterol, 2018, 24(31): 3513-3520. [24] Trivedi HD, Danford CJ, Goyes D, et al. Osteoporosis in primary biliary cholangitis: prevalence, impact and management challenges [J]. Clin Exp Gastroenterol, 2020, 13:17-24. doi: 10.2147/CEG.S204638. [25] Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the study of liver diseases [J]. Hepatology, 2019, 69(1): 394-419. [26] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis [J]. J Hepatol, 2017, 67(1): 145-172. [27] Rudic JS, Giljaca V, Krstic MN, et al. Bisphosphonates for osteoporosis in primary biliary cirrhosis [J]. Cochrane Database Syst Rev, 2011,(12): CD009144. doi: 10.1002/14651858.CD009144.pub2. [28] Guañabens N, Monegal A, Cerdá D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis [J]. Hepatology, 2013, 58(6): 2070-2078. [29] Rudic JS, Poropat G, Krstic MN, et al. Hormone replacement for osteoporosis in women with primary biliary cirrhosis [J]. Cochrane Database Syst Rev, 2011,(12): CD009146. doi: 10.1002/14651858.CD009146.pub2. [30] Danford CJ, Ezaz G, Trivedi HD, et al. The pharmacologic management of osteoporosis in primary biliary cholangitis: a systematic review and meta-analysis [J]. J Clin Densitom, 2020, 23(2): 223-236. [31] Xu X, Wang R, Wu R, et al. Trehalose reduces bone loss in experimental biliary cirrhosis rats via ERK phosphorylation regulation by enhancing autophagosome formation [J]. FASEB J, 2020, 34(6): 8402-8415. |
| [1] | . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(9): 131-132. |
| [2] | ZHANG Chong-yun. Half-hepatic blood flow occlusion for hepatolithiasis at normal atmospheric temperature [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(1): 106-108. |
|
